1
|
Dong G, Jiang Y, Zhang F, Zhu F, Liu J, Xu Z. Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017-present): The anticancer activity, structure-activity relationships, and mechanisms of action. Arch Pharm (Weinheim) 2023; 356:e2200479. [PMID: 36372519 DOI: 10.1002/ardp.202200479] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2022] [Revised: 10/17/2022] [Accepted: 10/20/2022] [Indexed: 11/15/2022]
Abstract
Cancer is one of the leading causes of death across the world, and the prevalence and mortality rates of cancer will continue to grow. Chemotherapeutics play a critical role in cancer therapy, but drug resistance and side effects are major hurdles to effective treatment, evoking an immediate need for the discovery of new anticancer agents. Triazines including 1,2,3-, 1,2,4-, and 1,3,5-triazine have occupied a propitious place in drug design and development due to their excellent pharmacological profiles. Mechanistically, triazine derivatives could interfere with various signaling pathways to induce cancer cell death. Hence, triazine derivatives possess potential in vitro and in vivo efficacy against diverse cancers. In particular, triazine hybrids are able to overcome drug resistance and reduce side effects. Moreover, several triazine hybrids such as brivanib (indole-containing pyrrolo[2,1-f][1,2,4]triazine), gedatolisib (1,3,5-triazine-urea hybrid), and enasidenib (1,3,5-triazine-pyridine hybrid) have already been available in the market. Accordingly, triazine hybrids are useful scaffolds for the discovery of novel anticancer chemotherapeutics. This review focuses on the anticancer activity of 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids, together with the structure-activity relationships and mechanisms of action developed from 2017 to the present. The enriched structure-activity relationships may be useful for further rational drug development of triazine hybrids as potential clinical candidates.
Collapse
Affiliation(s)
- Gaoli Dong
- School of Chemistry and Pharmaceutical Engineering, Huanghuai University, Zhumadian, China
| | - Yingchun Jiang
- College of Medicine, Huanghuai University, Zhumadian, China
| | - Feng Zhang
- School of Chemistry and Pharmaceutical Engineering, Huanghuai University, Zhumadian, China
| | - Fengyun Zhu
- College of Biology and Food Engineering, Huanghuai University, Zhumadian, China
| | - Junna Liu
- Industry Innovation & Research and Development Institute of Zhumadian, Huanghuai University, Zhumadian, China
| | - Zhi Xu
- Industry Innovation & Research and Development Institute of Zhumadian, Huanghuai University, Zhumadian, China
| |
Collapse
|
2
|
New synthetic quinaldine conjugates: Assessment of their anti-cholinesterase, anti-tyrosinase and cytotoxic activities, and molecular docking analysis. ARAB J CHEM 2022. [DOI: 10.1016/j.arabjc.2022.104177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
3
|
Maliszewski D, Drozdowska D. Recent Advances in the Biological Activity of s-Triazine Core Compounds. Pharmaceuticals (Basel) 2022; 15:ph15020221. [PMID: 35215333 PMCID: PMC8875733 DOI: 10.3390/ph15020221] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Revised: 02/05/2022] [Accepted: 02/10/2022] [Indexed: 12/18/2022] Open
Abstract
An effective strategy for successful chemotherapy relies on creating compounds with high selectivity against cancer cells compared to normal cells and relatively low cytotoxicity. One such approach is the discovery of critical points in cancer cells, i.e., where specific enzymes that are potential therapeutic targets are generated. Triazine is a six-membered heterocyclic ring compound with three nitrogen replacing carbon-hydrogen units in the benzene ring structure. The subject of this review is the symmetrical 1,3,5-triazine, known as s-triazine. 1,3,5-triazine is one of the oldest heterocyclic compounds available. Because of its low cost and high availability, it has attracted researcher attention for novel synthesis. s-Triazine has a weak base, it has much weaker resonance energy than benzene, therefore, nucleophilic substitution is preferred to electrophilic substitution. Heterocyclic bearing a symmetrical s-triazine core represents an interesting class of compounds possessing a wide spectrum of biological properties such as anti-cancer, antiviral, fungicidal, insecticidal, bactericidal, herbicidal and antimicrobial, antimalarial agents. They also have applications as dyes, lubricants, and analytical reagents. Hence, the group of 1,3,5-triazine derivatives has developed over the years. Triazine is not only the core amongst them, but is also a factor increasing the kinetic potential of the entire derivatives. Modifying the structure and introducing new substituents makes it possible to obtain compounds with broad inhibitory activity on processes such as proliferation. In some cases, s-triazine derivatives induce cell apoptosis. In this review we will present currently investigated 1,3,5-triazine derivatives with anti-cancer activities, with particular emphasis on their inhibition of enzymes involved in the process of tumorigenesis.
Collapse
|
4
|
Identification and Validation of Autophagy-Related Gene Nomograms to Predict the Prognostic Value of Patients with Cervical Cancer. JOURNAL OF ONCOLOGY 2021; 2021:5583400. [PMID: 34257653 PMCID: PMC8253645 DOI: 10.1155/2021/5583400] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 05/21/2021] [Accepted: 06/14/2021] [Indexed: 01/06/2023]
Abstract
Autophagy is a process of engulfing one's own cytoplasmic proteins or organelles and coating them into vesicles, fusing with lysosomes to form autophagic lysosomes, and degrading the contents it encapsulates. Increasing studies have shown that autophagy disorders are closely related to the occurrence of tumors. However, the prognostic role of autophagy genes in cervical cancer is still unclear. In this study, we constructed risk signatures of autophagy-related genes (ARGs) to predict the prognosis of cervical cancer. The expression profiles and clinical information of autophagy gene sets were downloaded from TCGA and GSE52903 queues as training and validation sets. The normal cervical tissue expression profile data from the UCSC XENA website (obtained from GTEx) were used as a supplement to the TCGA normal cervical tissue. Univariate COX regression analysis of 17 different autophagy genes was performed with the consensus approach. Tumor samples from TCGA were divided into six subtypes, and the clinical traits of the six subtypes had different distributions. Further absolute shrinkage and selection operator (LASSO) and multivariable COX regression yielded an autophagy genetic risk model consisting of eight genes. In the training set, the survival rate of the high-risk group was lower than that of the low-risk group (p < 0.0001). In the validation set, the AUC area of the receiver operating characteristic (ROC) curve was 0.772 for the training set and 0.889 for the verification set. We found that high and low risk scores were closely related to TNM stage (p < 0.05). The nomogram shows that the risk score combined with other indicators, such as G, T, M, and N, better predicts 1-, 3-, and 5-year survival rates. Decline curve analysis (DCA) shows that the risk model combined with other indicators produces better clinical efficacy. Immune cells with an enrichment score of 28 showed statistically significant differences related to high and low risk. GSEA enrichment analysis showed the main enrichment being in KRAS activation, genes defining epithelial and mesenchymal transition (EMT), raised in response to the low oxygen level (hypoxia) gene and NF-kB in response to TNF. These pathways are closely related to the occurrence of tumors. Our constructed autophagy risk signature may be a prognostic tool for cervical cancer.
Collapse
|
5
|
Jain S, Jain PK, Sain S, Kishore D, Dwivedi J. Anticancer s-Triazine Derivatives: A Synthetic Attribute. MINI-REV ORG CHEM 2020. [DOI: 10.2174/1570193x17666200131111851] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
1, 3, 5-Triazine (s-Triazine) is a versatile nucleus to design and develop potent bioactive
molecules for drug discovery, particularly in cancer therapy. The aim of this review is to present the
most recent trends in the field of synthetic strategies made for functionalized triazine derivatives active
against cell proliferation. This review article covers the synthesis of aryl methylamino, morpholino,
triamino substituted triazines, antimitotic agents coupled triazines and many more. Many 1,3,5-
triazine derivatives, both hetero-fused and uncondensed, have shown remarkable antitumor activities.
We have highlighted various derivatives with 1, 3, 5-triazine core targeting different kinases with an
aim to help researchers for developing new 1, 3, 5-triazine derived compounds for antitumor activity.
Collapse
Affiliation(s)
- Sonika Jain
- Department of Chemistry, Banasthali Vidyapith, Banasthali-304022, India
| | - Pankaj Kumar Jain
- Department of Pharmacy, Banasthali Vidyapith, Banasthali-304022, India
| | - Shalu Sain
- Department of Chemistry, Banasthali Vidyapith, Banasthali-304022, India
| | - Dharma Kishore
- Department of Chemistry, Banasthali Vidyapith, Banasthali-304022, India
| | - Jaya Dwivedi
- Department of Chemistry, Banasthali Vidyapith, Banasthali-304022, India
| |
Collapse
|
6
|
Guo H, Diao QP. 1,3,5-Triazine-azole Hybrids and their Anticancer Activity. Curr Top Med Chem 2020; 20:1481-1492. [DOI: 10.2174/1568026620666200310122741] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2020] [Revised: 02/12/2020] [Accepted: 02/17/2020] [Indexed: 12/24/2022]
Abstract
1,3,5-Triazine and azole can interact with various therapeutic targets, and their derivatives
possess promising in vitro and in vivo anticancer activity. Hybrid molecules have the potential to enhance
efficiency, overcome drug resistance and reduce side effects, and many hybrid molecules are under
different phases of clinical trials, so hybridization of 1,3,5-triazine with azole may provide valuable
therapeutic intervention for the treatment of cancer. Substantial efforts have been made to develop
azole-containing 1,3,5-triazine hybrids as novel anticancer agents, and some of them exhibited excellent
activity. This review emphasizes azole-containing 1,3,5-triazine hybrids with potential anticancer activity,
and the structure-activity relationships as well as the mechanisms of action are also discussed to
provide comprehensive and target-oriented information for the development of this kind of anticancer
drugs.
Collapse
Affiliation(s)
- Hua Guo
- School of Chemistry and Life Science, Anshan Normal University, Anshan, Liaoning, China
| | - Quan-Ping Diao
- School of Chemistry and Life Science, Anshan Normal University, Anshan, Liaoning, China
| |
Collapse
|
7
|
Guo Q, Zhang Q, Lu L, Xu Y. Long noncoding RNA RUSC1-AS1 promotes tumorigenesis in cervical cancer by acting as a competing endogenous RNA of microRNA-744 and consequently increasing Bcl-2 expression. Cell Cycle 2020; 19:1222-1235. [PMID: 32264732 DOI: 10.1080/15384101.2020.1749468] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
The expression of a long noncoding RNA termed RUSC1-AS1 is dysregulated in breast cancer and laryngeal squamous cell carcinoma, and this dysregulation affects various tumor-associated biological processes. To our knowledge, the expression status and detailed roles of RUSC1-AS1 in cervical cancer as well as its regulatory mechanisms of action remain unknown. Therefore, the objectives of this study were to measure RUSC1-AS1 expression in cervical cancer, investigate the effects of RUSC1-AS1 on cervical cancer cells, and identify the mechanism underlying these effects. Herein, RUSC1-AS1 was found to be highly expressed in cervical cancer tissues and cell lines. High RUSC1-AS1 expression significantly correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage, lymph node metastasis, and shorter overall survival among the patients with cervical cancer. Functional assays revealed that interference with RUSC1-AS1 expression suppressed cervical cancer cell proliferation, migration, and invasion in vitro; induced apoptosis in vitro; and impeded tumor growth in vivo. In addition, RUSC1-AS1 was demonstrated to act as a competing endogenous RNA of microRNA-744 (miR-744) and consequently increase B-cell lymphoma 2 (Bcl-2 or BCL2) expression levels in cervical cancer cells. Furthermore, either inhibition of miR-744 or restoration of Bcl-2 expression neutralized the effects of the RUSC1-AS1 silencing on the malignant characteristics of cervical cancer cells. Thus, RUSC1-AS1 promotes the aggressiveness of cervical cancer in vitro and in vivo by upregulating miR-744-Bcl-2 axis output. The RUSC1-AS1-miR-744-Bcl-2 pathway may be involved in cervical cancer pathogenesis and could serve as a novel target for anticancer therapies.
Collapse
Affiliation(s)
- Qizhen Guo
- Department of Gynaecology and Obstetrics, Gaomi People's Hospital, Gaomi, Shandong, P.R. China
| | - Qin Zhang
- Department of Neurosurgery, Gaomi People's Hospital, Gaomi, Shandong, P.R. China
| | - Lianwei Lu
- Department of Radiology, Weifang People's Hospital, Weifang, Shandong, P.R. China
| | - Yanping Xu
- Department of General Surgery, Gaomi People's Hospital, Gaomi, Shandong, P.R. China
| |
Collapse
|
8
|
Ji L, Jiang X, Mao F, Tang Z, Zhong B. miR‑589‑5p is downregulated in prostate cancer and regulates tumor cell viability and metastasis by targeting CCL‑5. Mol Med Rep 2019; 20:1373-1382. [PMID: 31173214 DOI: 10.3892/mmr.2019.10334] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Accepted: 03/13/2019] [Indexed: 11/06/2022] Open
Abstract
Prostate cancer is one of the most common human malignancies, which represents a serious threat to health, and microRNAs (miRNAs/miRs) have been reported to be closely associated with the progression and development of prostate cancer. The present study aimed to investigate the expression patterns, functions and underlying mechanisms of miR‑589‑5p in prostate cancer. The results demonstrated that the expression levels of miR‑589‑5p were downregulated in prostate cancer tissues and cell lines. Overexpression of miR‑589‑5p inhibited cell viability, migration and invasion in prostate cancer cells. Subsequently, chemokine (C‑C motif) ligand 5 (CCL‑5) was identified as a direct target gene of miR‑589‑5p, which was highly expressed at the mRNA and protein levels in prostate cancer tissues and cells. Furthermore, CCL‑5 mRNA was negatively correlated with miR‑589‑5p expression in prostate cancer tissues. Silencing CCL‑5 promoted the apoptosis, and inhibited the migration and invasion of prostate cancer cells. Taken together, these results indicated that miR‑589‑5p may act as a tumor suppressor in prostate cancer by targeting CCL‑5, thus suggesting that miR‑589‑5p may be a novel and reliable molecular marker for the diagnosis and prognosis of prostate cancer.
Collapse
Affiliation(s)
- Lu Ji
- Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
| | - Xi Jiang
- Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
| | - Fei Mao
- Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
| | - Zhiwang Tang
- Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
| | - Bing Zhong
- Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
| |
Collapse
|
9
|
Mao BD, Xu P, Zhong Y, Ding WW, Meng QZ. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci 2019. [DOI: 10.1007/s12038-019-9851-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|